| Bioactivity | MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research[1]. |
| Invitro | MDVN1003 (0.1, 1 μM, 30 分钟预处理) 抑制 IgM 诱导的 pAKT、pERK 和 IgD 诱导的 B 细胞活化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MDVN1003 相关抗体: |
| CAS | 2058116-52-0 |
| Formula | C22H20FN7O |
| Molar Mass | 417.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alfaro J, et al. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies. J Pharmacol Exp Ther. 2017 May;361(2):312-321. |